Experimental cell therapy takes on advanced kidney cancer

NCT ID NCT06819293

Recruiting now Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new treatment called IB-T101 for people with advanced clear cell kidney cancer. The treatment uses a patient's own immune cells, called tumor-infiltrating lymphocytes, which are grown in a lab and then given back to the patient. The study will enroll 12 adults to check if the therapy is safe and if it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IB-T101 (a type of immune cell therapy using the patient's own tumor-infiltrating lymphocytes)
What this could lead to: If it works, this could point toward a new treatment option for advanced clear cell kidney cancer that has not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 12 people, so it is too soon to know if the treatment is effective or safe. There may be significant side effects from the cell therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT ADVANCED CLEAR RENAL CELL CARCINOMA

Contacts and locations

Locations

Tongji hospital, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.